The concept underpinning all of Ambicare’s technology has been to replicate the science of light therapies already clinically proven and practiced in central medical facilities, but to deliver them in a highly convenient form for use in community medicine or home settings, through use of convenient, wearable LED treatment heads and a rechargeable treatment controller.
Since its founding as the result of pioneering work done at the University of St. Andrews and Tayside Health Board (NHS) in 2004, Ambicare has made substantial progress in the development and commercialisation of proprietary, light emitting diode (LED) based devices for the treatment of a range of skin conditions and diseases. Ambicare has developed two distinct product lines, both of which are clinically proven and convenient to use, for the treatment of specific dermatological conditions: non-melanoma skin cancer and acne.
In the treatment of acne, blue light alone is the treatment mechanism ( Lustre Pure Light); in the case of non-melanoma skin cancer (and related conditions), red light is used in conjunction with proprietary topical pharmaceutical actives – a treatment described as Photo Dynamic Therapy (Ambulight PDT).
Ambicare’s patented platform technology allows the user to ‘wear’ the light delivery device, powered by a rechargeable controller, in daily use, enabling the treatment to be delivered in safe and gentle doses, avoiding the necessity of being ‘tied’ to a static light source in a physician’s surgery or hospital environment. This key point of difference not only enhances user convenience but also delivers improved end results through consistency of the light delivery to the skin.
Ambicare is an ISO 13485:2003 certified company.
This certification demonstrates the company has a quality management system that is able to provide medical devices and related services that consistently meet customer and regulatory requirements.